Existing cancer drug could be repurposed to fight certain aggressive
cancers

Date:
July 10, 2023
Source:
Nanyang Technological University
Summary:
A team of scientists has found that an existing cancer drug could
be repurposed to target a subset of cancers that currently lack
targeted treatment options and is often associated with poor
outcomes. This subset of cancers makes up 15 per cent of all
cancers and is especially prevalent in aggressive tumors such as
osteosarcoma (bone tumor) and glioblastoma (brain tumor).


Facebook Twitter Pinterest LinkedIN Email

==========================================================================
FULL STORY ==========================================================================
A team of scientists led by Nanyang Technological University, Singapore
(NTU Singapore) has found that an existing cancer drug could be repurposed
to target a subset of cancers that currently lack targeted treatment
options and is often associated with poor outcomes.

This subset of cancers makes up 15 per cent of all cancers and is
especially prevalent in aggressive tumours such as osteosarcoma (bone
tumour) and glioblastoma (brain tumour).

These cancerous cells 'stay immortal' using a mechanism called
the alternative lengthening of telomeres (ALT), but the team has
demonstrated that ponatinib, a cancer drug approved by the US Food and
Drug Administration, blocks key steps in the ALT mechanism that leads
it to fail.

Reporting their findings based on laboratory experiments and preclinical
animal studies, the scientists found that ponatinib helped to shrink bone tumours (a type of ALT cancer) without causing weight loss, a common
side effect associated with cancer drugs. In mice with tumours treated
with ponatinib, they found a reduction in a biomarker for ALT cancer as compared to untreated mice.

The findings are published in the scientific journal Nature
Communications.

The researchers say that the findings move them a step closer to
developing a targeted therapeutic option for ALT cancers, which lack
clinically approved targeted treatments to date.

Dr Maya Jeitany and a team of researchers from the NTU School of
Biological Sciences, together with collaborators from the Cancer Science Institute of Singapore and the Yong Loo Lin School of Medicine, both at
the National University of Singapore (NUS), and the Genome Institute of Singapore at the Agency for Science, Technology and Research (A*STAR),
are seeking to address this unmet need.

Dr Jeitany, study lead and senior research fellow at NTU's School of
Biological Sciences, said: "A prominent feature of cancer is its ability
to evade cell death and acquire indefinite replication -- to stay
immortal, in other words - - which it can do through the alternative lengthening of telomeres (ALT) mechanism. While a sizeable portion of
cancer cells depend on this mechanism, there is no clinically approved
targeted therapy available.

"Through our study, we identified a novel signalling pathway in the ALT mechanism and showed that the FDA-approved drug ponatinib inhibits this
pathway and holds exceptional promise in stopping the growth of ALT cancer cells. Our findings may provide a new direction for the treatment of ALT cancers by repurposing an FDA-approved drug for these types of tumours." Commenting as an independent expert, Assistant Professor Valerie Yang,
medical oncologist with the Department of Lymphoma and Sarcoma at the
National Cancer Centre Singapore, said: "Sarcomas and glioblastomas are
both highly complex cancers that are more prevalent in young people and currently have limited treatment options. The identification of a drug
that is FDA-approved which can be repurposed to target ALT, an Achilles
heel in these cancers, is very exciting." The study aligns with NTU
2025, the University's five-year strategic plan, which aims to address humanity's grand challenges by responding to the needs and challenges
of healthy living.

How cancer cells replicate and grow Telomeres are protective "caps"
at the tips of every chromosome, which carries our DNA. With each cell division, a bit of the telomeres is naturally snipped off, until they
become too short, leading to cell death.

Most cancer cells bypass this process by activating an enzyme called telomerase, which lengthens the telomeres so that the cells can
replicate indefinitely. However, about 15 per cent of cancers lengthen
their telomeres through alternative pathways, rather than activating telomerase. This mechanism is known as the alternative lengthening of
telomeres (ALT).

To date, there is no clinically approved targeted treatment for ALT
cancers.

Furthermore, many ALT cancers, such as osteosarcoma and glioblastoma,
show resistance to chemotherapy, highlighting the need for a more targeted
form of treatment.

Drug affects telomeres in ALT cancer cells Through high-throughput drug screening -- a process of screening large numbers of relevant biological
or pharmacological compounds -- and subsequent testing of shortlisted compounds, the scientists discovered that ponatinib, a drug approved by
the US Food and Drug Administration for a type of bone marrow cancer,
can kill ALT cancer cells effectively.

When osteosarcoma and liposarcoma (a tumour that grows in fatty tissues)
cells were treated with ponatinib, the scientists found that the drug
led to DNA damage, dysfunctional telomeres, and triggered senescence,
a process in which the cell stops dividing. Importantly, the synthesis
of telomeres in the cells also dropped after 18 to 20 hours of treatment
with the drug.

Pre-clinical studies conducted on mice that had received transplants of
human bone cancer cells further validated the potential of ponatinib. The
drug reduced the tumour sizes without affecting the mice's body weight,
a common side effect associated with cancer treatments.

In mice with tumours treated with ponatinib, there was also a reduction in
a biomarker for ALT cancer as compared to untreated mice -- an indicator
that the drug was effective in inhibiting ALT cancer growth.

The scientists ran further tests to identify ponatinib's mode of action
on telomeres in ALT cancer cells and identified a signalling pathway
(a series of chemical reactions in which a group of molecules in a cell
work together to control a cell function) that could be responsible for
the drug's effect on ALT.

The researchers are now studying further how ponatinib affects
telomeres to understand in more detail the signalling pathway they
have identified. They are also assessing potential ponatinib-based combinatorial drug treatments for ALT cancers.

* RELATED_TOPICS
o Health_&_Medicine
# Cancer # Breast_Cancer # Lung_Cancer # Brain_Tumor
o Mind_&_Brain
# Addiction # Illegal_Drugs # Huntington's_Disease #
Ecstasy
* RELATED_TERMS
o Brain_tumor o Cancer o Colorectal_cancer o
Monoclonal_antibody_therapy o HPV_vaccine o Stomach_cancer o
Malignant_melanoma o Bone_marrow

==========================================================================

Print

Email

Share ========================================================================== ****** 1 ****** ***** 2 ***** **** 3 ****
*** 4 *** ** 5 ** Breaking this hour ==========================================================================
* Six_Foods_to_Boost_Cardiovascular_Health
* Cystic_Fibrosis:_Lasting_Improvement *
Artificial_Cells_Demonstrate_That_'Life_...

* Advice_to_Limit_High-Fat_Dairy_Foods_Challenged
* First_Snapshots_of_Fermion_Pairs *
Why_No_Kangaroos_in_Bali;_No_Tigers_in_Australia
* New_Route_for_Treating_Cancer:_Chromosomes *
Giant_Stone_Artefacts_Found:_Prehistoric_Tools
* Astonishing_Secrets_of_Tunicate_Origins *
Most_Distant_Active_Supermassive_Black_Hole

Trending Topics this week ========================================================================== HEALTH_&_MEDICINE Cholesterol Healthy_Aging Mental_Health_Research
MIND_&_BRAIN Intelligence Depression Educational_Psychology LIVING_&_WELL Healthy_Aging Behavior Spirituality


==========================================================================

Strange & Offbeat ========================================================================== HEALTH_&_MEDICINE These_Lollipops_Could_'Sweeten'_Diagnostic_Testing_for_Kids_and_Adults_Alike Holograms_for_Life:_Improving_IVF_Success Grocery_Store_Carts_Set_to_Help_Diagnose_Common_Heart_Rhythm_Disorder_and Prevent_Stroke MIND_&_BRAIN
AI_Tests_Into_Top_1%_for_Original_Creative_Thinking Everyone's_Brain_Has_a_Pain_Fingerprint_--_New_Research_Has_Revealed_for_the First_Time Scientists_Discover_Spiral-Shaped_Signals_That_Organize_Brain_Activity LIVING_&_WELL Illusions_Are_in_the_Eye,_Not_the_Mind Amputees_Feel_Warmth_in_Their_Missing_Hand Why_Do_Champagne_Bubbles_Rise_the_Way_They_Do?_Scientists'_New_Discovery_Is Worthy_of_a_Toast Story Source: Materials provided by Nanyang_Technological_University. Note: Content may be edited for style
and length.


========================================================================== Journal Reference:
1. Frances Karla Kusuma, Aishvaryaa Prabhu, Galen Tieo, Syed Moiz
Ahmed,
Pushkar Dakle, Wai Khang Yong, Elina Pathak, Vikas Madan, Yan
Yi Jiang, Wai Leong Tam, Dennis Kappei, Peter Dro"ge, H. Phillip
Koeffler, Maya Jeitany. Signalling inhibition by ponatinib disrupts
productive alternative lengthening of telomeres (ALT). Nature
Communications, 2023; 14 (1) DOI: 10.1038/s41467-023-37633-3 ==========================================================================

Link to news story: https://www.sciencedaily.com/releases/2023/07/230710113634.htm

--- up 1 year, 19 weeks, 10 hours, 50 minutes
* Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1:317/3)